Newer Approaches to Treatment of Bladder Cancer

Presented by:
Philippe E. Spiess
Search for other papers by Philippe E. Spiess in
Current site
Google Scholar
PubMed Close
 MD, MS, FRCSC
and
Thomas W. Flaig
Search for other papers by Thomas W. Flaig in
Current site
Google Scholar
PubMed Close
 MD
Volume/Issue:
Volume 23: Issue Supplement
Online Publication Date:
27 May 2025
DOI:
https://doi.org/10.6004/jnccn.2025.5005
Restricted access

Several clinical trials in bladder cancer have resulted in FDA approvals and subsequent revisions to the NCCN Guidelines for Bladder Cancer. Cystectomy remains the primary treatment approach for bacillus Calmette-Guérin—unresponsive non–muscle-invasive bladder cancer (MIBC); however, in patients for whom such surgical intervention is not feasible, several bladder-sparing approaches are now available. In addition to neoadjuvant chemotherapy followed by resection as an established standard for MIBC, perioperative or sandwich therapy with gemcitabine plus cisplatin plus durvalumab is now also an option. The systemic treatment landscape for MIBC and metastatic disease is expanding to further incorporate antibody–drug conjugates, immune checkpoint inhibitors, and targeted therapies.

Disclosures: Dr. Flaig has disclosed receiving grant/research support from Agensys, Inc., Astellas Pharma US, Inc., AstraZeneca Pharmaceuticals, Bristol Myers Squibb, Genentech, Inc., Janssen Pharmaceutica Products, Merck & Co., Inc., Sanofi-Aventis US, and Seagen Inc.; receiving consulting fees from Criterium, Inc.; and serving as a scientific advisor for Criterium, Inc. and Janssen Pharmaceutica Products. Dr. Spiess has disclosed no relevant financial relationships.

Correspondence: Philippe E. Spiess, MD, MS, FRCSC, Moffitt Cancer Center, 12902 Magnolia Drive, Office 12538, Tampa, FL 33612. Email: philippe.spiess@moffitt.org; and
Thomas W. Flaig, MD, University of Colorado Cancer Center, Mail Stop 8117, 12801 East 17th Avenue, Room L18-8117, Aurora, CO 80045. Email: thomas.flaig@ucdenver.edu
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Flaig TW, Spiess PE, Abern M, et al. NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. Version 1.2025. Accessed April 8, 2025. To view the most recent version, visit https://www.nccn.org

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Oddens J, Brausi M, Sylvester R, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 2013;63:462472.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Messing EM, Tangen CM, Lerner SP, et al. Effect of Intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial. JAMA 2018;319:18801888.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Taylor JI, Kamat AM, O’Donnell MA, et al. Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancer. BJU Int 2025;135:260–268.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Patel SH, Gabrielson AT, Chan S, et al. A phase 2 trial of intravesical gemcitabine and docetaxel in the treatment of bacillus Calmette-Guérin–naive nonmuscle-invasive urothelial carcinoma of the bladder. J Urol 2024;212:95–103.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Kamat AM, Sylvester RJ, Böhle A, et al. Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group. J Clin Oncol 2016;34:19351944.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Lerner SP, Tangen C, Svatek RS, et al. Standard or extended lymphadenectomy for muscle-invasive bladder cancer. N Engl J Med 2024;391:1206–1216.

  • 8.

    Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med 2021;384:1125–1135.

  • 9.

    Powles T, Tagawa S, Vulsteke C, et al. Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial. Ann Oncol 2025;36:561–571.

  • 10.

    Powles T, Valderrama BP, Gupta S, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med 2024;390:875–888.

  • 11.

    Rosenberg JE, Petrylak DP, Flaig T, et al. Study EV-103 dose escalation/cohort A: 5y follow-up of first-line enfortumab vedotin + pembrolizumab in cisplatin-ineligible locally advanced or metastatic urothelial carcinoma. Presented at the ESMO Congress 2024; September 13–17, 2024; Barcelona, Spain. Abstract 1968P.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    van der Heijden MS, Sonpavde G, Powles T, et al. Nivolumab plus gemcitabine–cisplatin in advanced urothelial carcinoma. N Engl J Med 2023;389:1778–1789.

  • 13.

    Powles T, Catto JWF, Galsky MD, et al. Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer. N Engl J Med 2024;391:1773–1786.

  • 14.

    Hoimes CJ, Bedke J, Loriot Y, et al. KEYNOTE-B15/EV-304: randomized phase 3 study of perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC). J Clin Oncol 2021;39(Suppl):TPS4587.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med 2019;381:338348.

  • 16.

    US Food & Drug Administration. FDA approved erdafitinib for locally advanced or metastatic urothelial carcinoma. Accessed May 9, 2025. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-erdafitinib-locally-advanced-or-metastatic-urothelial-carcinoma

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol 2024;42:47–58.

    • PubMed
    • Search Google Scholar
    • Export Citation
Copyright:
Copyright © 2025 by the National Comprehensive Cancer Network 2025
Article Category:
Abstract
Print Publication Date:
01 May 2025
Online Publication Date:
27 May 2025

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 306 306 306
PDF Downloads 172 172 172
EPUB Downloads 0 0 0